Business Wire

NIPPON KINZOKU's Stainless Steel Wide Width Foil (BS/WS Finish)

29.8.2024 18:01:00 EEST | Business Wire | Press release

Share

NIPPON KINZOKU CO., LTD. (TOKYO: 5491) (Headquarters: Minato-ku, Tokyo) produces stainless steel foil by our proprietary technology for the automotive, battery, semiconductor and other markets. Our stainless steel foil features high precision, wide width and large unit weight, contributing to customers' productivity improvement, yield improvement and process reduction. In addition, we offer two types of finishes, "BS: Bright Surface" and "WS: White Surface," to meet the needs for surface design and functionality.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829255660/en/

NIPPON KINZOKU's stainless steel foil features high precision, wide width and large unit weight. In addition, we offer two types of finishes, "BS: Bright Surface" and "WS: White Surface," to meet the needs for surface design and functionality. (Graphic: Business Wire)

NIPPON KINZOKU's Stainless Steel Wide Width Foil

Steel grade:

All steel grades (SUS304, SUS301, SUS430, etc.)

Finish:

Spring finish, TA finish (Tension Annealing), BA finish (Bright Annealing)

Features:

1. Wide Width: Max. 600mm

2. High Precision: Min. longitudinal variation of thickness ±1μm

3. Surface: Bright Surface (BS), White Surface (WS)

4. Unit weight: Max. 0.5kg/mm

5. Min. thickness: 0.02mm

Applications

One of the features of our stainless steel foils is that we produce wide width foil.
Applications include surface heating elements used in automobiles, FPC reinforcement plates, and metal masks used in electronic devices, and are used as composite materials with films etc. attached. In particular, there are few material manufacturers that produce materials with thickness of less than 30 μm and a width of nearly 600 mm, contributing to improved processing yields and productivity.

Surface texture

We meet various requirements for surface texture depending on the application.
In tact switch applications, there is concern about cracking due to minute surface irregularities during repeated use. In such cases, we recommend a Bright surface (BS finish) with a smooth surface, which contributes to improved durability.
For the exterior of rechargeable batteries and connectors, on the contrary, we recommend a rougher White surface (WS finish), which contributes to improved adhesion with adhesives (exterior of rechargeable batteries) and visibility of laser engraving on the product surface (connectors).

About NIPPON KINZOKU Group

Our products have been used in a range of areas from the precision field to the construction industry. https://www.nipponkinzoku.co.jp/en/

Click here for the full text.
https://www.nipponkinzoku.co.jp/assets/images/2024/08/NIPPON-KINZOKUs-Stainless-Steel-Wide-Width-Foil-BSWS-Finish.pdf

View source version on businesswire.com: https://www.businesswire.com/news/home/20240829255660/en/

Contacts

Sales Development Dept.
NIPPON KINZOKU CO., LTD.
E-mail: nikkin-overseas@nipponkinzoku.co.jp
https://www.nipponkinzoku.co.jp/en/inquiry -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nipponkinz
oku.co.jp%2Fen%2Finquiry&esheet=54114420&newsitemid=20240829255660&lan=en-US&anc
hor=https%3A%2F%2Fwww.nipponkinzoku.co.jp%2Fen%2Finquiry&index=3&md5=85f599e0877
6ee98cf617fc77bafe4dc

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye